Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mTc) tropantiol
- Development stage
- Unknown
- Lead developer
- Global Medical Solutions
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
technetium (99mTc) tropantiol (commonly known as TRODAT-1) is a technetium-99m-labeled tropane derivative that acts as a radiopharmaceutical imaging agent. It selectively binds to the presynaptic sodium-dependent dopamine transporter (DAT) in the striatum. Developed as a single-photon emission computed tomography (SPECT) tracer, it is used for the non-invasive in vivo evaluation of dopaminergic neuron integrity, aiding in the early diagnosis, staging, and differential diagnosis of Parkinson's disease and other parkinsonian syndromes (such as differentiating them from essential tremor). The agent was originally developed by researchers at the University of Pennsylvania, led by Dr. Hank F. Kung, and was subsequently commercialized by the Institute of Nuclear Energy Research (INER) of Taiwan and Global Medical Solutions.
- Brand names
- DOPA-TEC
- Other names
- 99mTc-TRODAT-1TRODATtechnetium (99m Tc) tropantioltechnetium Tc 99m TRODAT-1technetium Tc 99m tropantioltropantioltropantiol (99m Tc)tropantiol (99mTc)
02
Targets
DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on technetium (99mTc) tropantiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mTc) tropantiol.